Is lMO2 a novel predictive marker for a better prognosis in pancreatic cancer?
LMO2 is a promising marker for predicting a better prognosis in pancreatic cancer.
Individual short-term intraoperative changes of tCa or iCa are not predictive for successful PTX, as they more likely reflect changes in intraoperative fluid management rather than decreased iPTH.